Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.C04 alone and with Keytruda in recurrent or metastatic head and neck squamous cell carcinoma
2023-505145-93-00Phase 2Completed
- Sponsor
- Alentis Therapeutics
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of ALE-C04 in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Alentis Therapeutics. Primary endpoints: Dose-limiting toxicities, Safety and 4 more. Started Dec 2023; status: completed.
02
Drugs
ALE-C04
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-505145-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505145-93-00.